CTT Pharmaceutical Holdings Inc
CTT Pharmaceutical Holdings, Inc. engages in the development of oral drug delivery systems for pain management and treatment. It focuses on fast dissolving drug delivery systems. The company's technology platform includes the development of advanced oral delivery thin wafers infused with both natural and/or synthetic cannabis extracts to deliver treatment as an alternate to smoking and ingestion.… Read more
CTT Pharmaceutical Holdings Inc (CTTH) - Net Assets
Latest net assets as of June 2025: $82.14K USD
Based on the latest financial reports, CTT Pharmaceutical Holdings Inc (CTTH) has net assets worth $82.14K USD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($102.17K) and total liabilities ($20.03K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $82.14K |
| % of Total Assets | 80.4% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | -90.4% |
| Growth Volatility | 8708.5 |
CTT Pharmaceutical Holdings Inc - Net Assets Trend (1999–2024)
This chart illustrates how CTT Pharmaceutical Holdings Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for CTT Pharmaceutical Holdings Inc (1999–2024)
The table below shows the annual net assets of CTT Pharmaceutical Holdings Inc from 1999 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $32.18K | -46.39% |
| 2023-12-31 | $60.03K | -32.73% |
| 2022-12-31 | $89.25K | +1591.62% |
| 2021-12-31 | $5.28K | +101.84% |
| 2020-12-31 | $-286.77K | -333.58% |
| 2019-12-31 | $122.77K | -75.45% |
| 2018-12-31 | $500.10K | +658.27% |
| 2017-12-31 | $-89.58K | +15.38% |
| 2016-12-31 | $-105.86K | -131.59% |
| 2015-12-31 | $335.13K | -42.87% |
| 2014-12-31 | $586.63K | +1981.13% |
| 2014-02-28 | $-31.18K | +87.17% |
| 2013-12-31 | $-243.13K | +37.07% |
| 2012-12-31 | $-386.33K | -184.64% |
| 2011-12-31 | $456.45K | +33786.41% |
| 2010-12-31 | $1.35K | +100.11% |
| 2009-12-31 | $-1.25 Million | -924.82% |
| 2008-12-31 | $151.39K | -72.86% |
| 2007-12-31 | $557.86K | -27.08% |
| 2006-12-31 | $765.03K | +930.92% |
| 2005-12-31 | $74.21K | -96.13% |
| 2004-12-31 | $1.92 Million | +212.13% |
| 2003-12-31 | $-1.71 Million | -196.14% |
| 2002-12-31 | $-577.76K | -3181.24% |
| 2001-12-31 | $-17.61K | +79.96% |
| 2000-12-31 | $-87.85K | -5.28% |
| 1999-12-31 | $-83.44K | -- |
Equity Component Analysis
This analysis shows how different components contribute to CTT Pharmaceutical Holdings Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 638532200.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $5.41K | 16.80% |
| Other Components | $7.42 Million | 23062.90% |
| Total Equity | $32.18K | 100.00% |
CTT Pharmaceutical Holdings Inc Competitors by Market Cap
The table below lists competitors of CTT Pharmaceutical Holdings Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Indigo Exploration Inc.
PINK:IXIXF
|
$1.49 Million |
|
Solvbl Solutions Inc
PINK:SOLBF
|
$1.49 Million |
|
Alma Gold Inc
PINK:ALGLF
|
$1.49 Million |
|
Haloni Jane
JK:HALO
|
$1.50 Million |
|
INSMED
BE:IM8N
|
$1.49 Million |
|
ATI Physical Therapy Inc
NYSE:ATIP
|
$1.49 Million |
|
EQUIFAX INC - Dusseldorf Stock Exchang
DU:EFX
|
$1.49 Million |
|
MetaVia Inc.
NASDAQ:MTVA
|
$1.49 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in CTT Pharmaceutical Holdings Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 60,035 to 32,183, a change of -27,852 (-46.4%).
- Net loss of 210,000 reduced equity.
- Other comprehensive income decreased equity by 2,073.
- Other factors increased equity by 184,221.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-210.00K | -652.52% |
| Other Comprehensive Income | $-2.07K | -6.44% |
| Other Changes | $184.22K | +572.42% |
| Total Change | $- | -46.39% |
Book Value vs Market Value Analysis
This analysis compares CTT Pharmaceutical Holdings Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 84.67x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1999-12-31 | $-17.45 | $0.05 | x |
| 2000-12-31 | $-11.04 | $0.05 | x |
| 2001-12-31 | $-1.21 | $0.05 | x |
| 2002-12-31 | $-1.21 | $0.05 | x |
| 2003-12-31 | $-4.11 | $0.05 | x |
| 2004-12-31 | $4.70 | $0.05 | x |
| 2005-12-31 | $0.13 | $0.05 | x |
| 2006-12-31 | $1.31 | $0.05 | x |
| 2007-12-31 | $0.87 | $0.05 | x |
| 2008-12-31 | $0.22 | $0.05 | x |
| 2009-12-31 | $-1.53 | $0.05 | x |
| 2010-12-31 | $-0.38 | $0.05 | x |
| 2011-12-31 | $0.48 | $0.05 | x |
| 2012-12-31 | $-0.41 | $0.05 | x |
| 2013-12-31 | $-0.26 | $0.05 | x |
| 2014-12-31 | $0.04 | $0.05 | x |
| 2015-12-31 | $0.02 | $0.05 | x |
| 2016-12-31 | $0.00 | $0.05 | x |
| 2017-12-31 | $0.00 | $0.05 | x |
| 2018-12-31 | $0.01 | $0.05 | x |
| 2019-12-31 | $0.00 | $0.05 | x |
| 2020-12-31 | $-0.01 | $0.05 | x |
| 2021-12-31 | $0.00 | $0.05 | x |
| 2022-12-31 | $0.00 | $0.05 | x |
| 2023-12-31 | $0.00 | $0.05 | x |
| 2024-12-31 | $0.00 | $0.05 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently CTT Pharmaceutical Holdings Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -652.52%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 2.27x
- Recent ROE (-652.52%) is below the historical average (-293.21%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1999 | 0.00% | -1669.59% | 3.88x | 0.00x | $-251.06K |
| 2000 | 0.00% | -69475800.00% | 0.01x | 0.00x | $-685.97K |
| 2001 | 0.00% | 0.00% | 0.00x | 0.00x | $-65.49K |
| 2002 | 0.00% | 0.00% | 0.00x | 0.00x | $-462.22K |
| 2003 | 0.00% | 0.00% | 0.00x | 0.00x | $-961.90K |
| 2004 | -29.24% | 0.00% | 0.00x | 1.13x | $-752.84K |
| 2005 | -2484.91% | -242631.58% | 0.00x | 29.08x | $-1.85 Million |
| 2006 | -164.18% | -41315.79% | 0.00x | 2.26x | $-1.33 Million |
| 2007 | -494.93% | 0.00% | 0.00x | 3.33x | $-2.82 Million |
| 2008 | -1043.68% | 0.00% | 0.00x | 10.23x | $-1.60 Million |
| 2009 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.50 Million |
| 2010 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.07 Million |
| 2011 | 819.15% | 0.00% | 0.00x | 9.16x | $3.69 Million |
| 2012 | 0.00% | 0.00% | 0.00x | 0.00x | $-964.37K |
| 2013 | 0.00% | 0.00% | 0.00x | 0.00x | $134.78K |
| 2014 | 0.00% | 0.00% | 0.00x | 0.00x | $-17.07K |
| 2014 | 38.84% | 0.00% | 0.00x | 2.83x | $169.18K |
| 2015 | -431.43% | 0.00% | 0.00x | 1.92x | $-1.48 Million |
| 2016 | 0.00% | 0.00% | 0.00x | 0.00x | $-632.41K |
| 2017 | 0.00% | -3452.50% | 0.21x | 0.00x | $-1.37 Million |
| 2018 | -345.53% | -6912.00% | 0.03x | 1.56x | $-1.78 Million |
| 2019 | -477.31% | -1190.96% | 0.09x | 4.67x | $-598.28K |
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $-557.32K |
| 2021 | -2520.85% | 0.00% | 0.00x | 20.41x | $-133.53K |
| 2022 | -59.89% | 0.00% | 0.00x | 1.05x | $-62.37K |
| 2023 | -70.32% | 0.00% | 0.00x | 1.32x | $-48.22K |
| 2024 | -652.52% | 0.00% | 0.00x | 2.27x | $-213.22K |
Industry Comparison
This section compares CTT Pharmaceutical Holdings Inc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $548,450,613
- Average return on equity (ROE) among peers: -450.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| CTT Pharmaceutical Holdings Inc (CTTH) | $82.14K | 0.00% | 0.24x | $1.49 Million |
| Ascend Wellness Holdings Inc (AAWH) | $142.87 Million | -33.75% | 5.44x | $48.90 Million |
| AB Science S.A (ABSCF) | $10.73 Million | -252.65% | 3.71x | $39.89 Million |
| Alterola Biotech Inc (ABTI) | $4.85K | -2005.32% | 0.49x | $603.58K |
| Aurora Cannabis Inc (ACB) | $2.04 Billion | -34.08% | 0.34x | $199.15 Million |
| Acreage Holdings Inc (ACRDF) | $204.27 Million | -30.85% | 1.41x | $13.48K |
| Acura Pharmaceuticals Inc (ACUR) | $7.90 Million | -63.15% | 1.15x | $13.20K |
| Agra Ventures Ltd. (AGFAF) | $1.51 Million | -44.22% | 0.06x | $298.23K |
| Allergy Therapeutics plc (AGYTF) | $2.07 Million | -2084.75% | 31.32x | $25.30 Million |
| Aida Pharmaceuticals Inc (AIDA) | $6.67 Million | 24.51% | 2.78x | $1.80 |
| Adcock Ingram Holdings Limited (AIHLF) | $3.07 Billion | 20.55% | 0.55x | $85.61 Million |